Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial

Open access
Taguchi, Isao, Iimuro, Satoshi, Iwata, Hiroshi, Takashima, Hiroaki, Abe, Mitsuru, Amiya, Eisuke, Ogawa, Takanori, Ozaki, Yukio, Sakuma, Ichiro, Nakagawa, Yoshihisa, Hibi, Kiyoshi, Hiro, Takafumi, Fukumoto, Yoshihiro, Hokimoto, Seiji, Miyauchi, Katsumi, Yamazaki, Tsutomu, Ito, Hiroshi, Otsuji, Yutaka, Kimura, Kazuo, Takahashi, Jun, Hirayama, Atsushi, Yokoi, Hiroyoshi, Kitagawa, Kazuo, Urabe, Takao, Okada, Yasushi, Terayama, Yasuo, Toyoda, Kazunori, Nagao, Takehiko, Matsumoto, Masayasu, Ohashi, Yasuo, Kaneko, Tetsuji, Fujita, Retsu, Ohtsu, Hiroshi, Ogawa, Hisao, Daida, Hiroyuki, Shimokawa, Hiroaki, Saito, Yasushi, Kimura, Takeshi, Inoue, Teruo, Matsuzaki, Masunori, Nagai, Ryozo·2018·Circulation

Abstract

Background: Current guidelines call for high-intensity statin therapy in patients with cardiovascular disease on the basis of several previous “more versus less statins” trials. However, no clear evidence for more versus less statins has been established in an Asian population. Methods: In this prospective, multicenter, randomized, open-label, blinded end point study, 13 054 Japanese patients with stable coronary artery disease who achieved low-density lipoprotein cholesterol (LDL-C) <120 mg/dL during a run-in period (pitavastatin 1 mg/d) were randomized in a 1-to-1 fashion to high-dose (pitavastatin 4 mg/d; n=6526) or low-dose (pitavastatin 1 mg/d; n=6528) statin therapy. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, or unstable angina requiring emergency hospitalization. The secondary composite end point was a composite of the primary end point and clinically indicated coronary revascularization excluding target-lesion revascularization at sites of prior percutaneous coronary intervention. Results: The mean age of the study population was 68 years, and 83% were male. The mean LDL-C level before enrollment was 93 mg/dL with 91% of patients taking statins. The baseline LDL-C level after the run-in period on pitavastatin 1 mg/d was 87.7 and 88.1 mg/dL in the high-dose and low-dose groups, respectively. During the entire course of follow-up, LDL-C in the high-dose group was lower by 14.7 mg/dL than in the low-dose group ( P <0.001). With a median follow-up of 3.9 years, high-dose as compared with low-dose pitavastatin significantly reduced the risk of the primary end point (266 patients [4.3%] and 334 patients [5.4%]; hazard ratio, 0.81; 95% confidence interval, 0.69–0.95; P =0.01) and the risk of the secondary composite end point (489 patients [7.9%] and 600 patients [9.7%]; hazard ratio, 0.83; 95% confidence interval, 0.73–0.93; P =0.002). High-dose pitavastatin also significantly reduced the risks of several other secondary end points such as all-cause death, myocardial infarction, and clinically indicated coronary revascularization. The results for the primary and the secondary composite end points were consistent across several prespecified subgroups, including the low (<95 mg/dL) baseline LDL-C subgroup. Serious adverse event rates were low in both groups. Conclusions: High-dose (4 mg/d) compared with low-dose (1 mg/d) pitavastatin therapy significantly reduced cardiovascular events in Japanese patients with stable coronary artery disease. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01042730.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.032615

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 243

Metadata

Authors
Taguchi, I., Iimuro, S., Iwata, H., Takashima, H., Abe, M., Amiya, E., Ogawa, T., Ozaki, Y., Sakuma, I., Nakagawa, Y., Hibi, K., Hiro, T., Fukumoto, Y., Hokimoto, S., Miyauchi, K., Yamazaki, T., Ito, H., Otsuji, Y., Kimura, K., Takahashi, J., Hirayama, A., Yokoi, H., Kitagawa, K., Urabe, T., Okada, Y., Terayama, Y., Toyoda, K., Nagao, T., Matsumoto, M., Ohashi, Y., Kaneko, T., Fujita, R., Ohtsu, H., Ogawa, H., Daida, H., Shimokawa, H., Saito, Y., Kimura, T., Inoue, T., Matsuzaki, M., & Nagai, R.
Venue
Circulation
Published
2018-05-08
Volume
137
Issue
19
Pages
1997-2009
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2801100099
Cited by
243
References
14
FWCI
26.39
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. https://app.cochat.ai/papers/10.1161/circulationaha.117.032615
The paper
Taguchi, I., Iimuro, S., Iwata, H., Takashima, H., Abe, M., Amiya, E., Ogawa, T., Ozaki, Y., Sakuma, I., Nakagawa, Y., Hibi, K., Hiro, T., Fukumoto, Y., Hokimoto, S., Miyauchi, K., Yamazaki, T., Ito, H., Otsuji, Y., Kimura, K., . . . Nagai, R. (2018). High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation. https://doi.org/10.1161/circulationaha.117.032615

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.